CorMedix
CRMD
7.28
0.00
0.00%
CorMedix
US · CRMD
#3663 by market cap
7.28
0.00
0.00%
Live - 5344 symbols - heartbeat 278s ago
· 2026-10-08 09:20
Pre-market
7.29
+0.14%
After-hours
7.30
+0.28%
Overnight
7.28
0.00%
- Market cap
- 567.43M
- P/E (TTM)i
- 3.34
- P/Bi
- 1.23
- EPSi
- 2.04
- Div yieldi
- 0.00%
- 52W posi
- 17%
Reader sentiment
Are you bullish or bearish on CRMD?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 1.77, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +617.03% YoY
Margins
- Gross margin
- 88.46%
- Operating margin
- 48.17%
- Net margin
- 51.99%
Key ratios & quality
- Enterprise valuei
- 564.98M
- Altman Z-Scorei
- 1.77
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 429.80K | 283.27K | 239.23K | 190.94K | 65.41K | 0 | 43.47M | 311.71M |
| Gross profit | 33.01K | -89.97K | 34.39K | 42.00K | 61.67K | 0 | 40.28M | 275.75M |
| Selling & admin expenses | 8.07M | 9.87M | 13.88M | 16.35M | 20.01M | 35.80M | 58.70M | 106.27M |
| Research & development | 18.82M | 11.05M | 13.38M | 13.13M | 10.68M | 13.16M | 3.94M | 19.33M |
| Operating profit | -26.86M | -21.01M | -27.22M | -29.44M | -30.62M | -48.96M | -22.36M | 150.14M |
| Pretax profit | -26.83M | -21.49M | -27.20M | -29.46M | -30.29M | -46.34M | -19.33M | 150.02M |
| Tax | 0 | -5.06M | -5.17M | -1.25M | -585.62K | 0 | -1.40M | -13.04M |
| Net profit | -26.83M | -16.43M | -22.03M | -28.21M | -29.70M | -46.34M | -17.93M | 163.06M |
| Basic EPS | -2 | -2 | -1 | -1 | -1 | -1 | 0 | 2 |
| Diluted EPS | -1.51 | -1.80 | -0.77 | -0.75 | -0.74 | -0.91 | -0.30 | 2.04 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 39.08M | -- | 104.28M | 128.62M | 127.43M | -- |
| Gross profit | 37.49M | 37.87M | 93.08M | 107.31M | 105.12M | 74.50M |
| Selling & admin expenses | 14.17M | 15.89M | 36.64M | 39.58M | 34.25M | 27.53M |
| Research & development | 3.19M | 2.44M | 5.10M | 8.60M | 7.21M | 6.68M |
| Operating profit | 20.13M | 19.54M | 51.35M | 59.13M | 63.66M | 42.91M |
| Pretax profit | 20.64M | 20.35M | 52.58M | 56.45M | 55.65M | 38.73M |
| Tax | 0 | 522.00K | -55.99M | 42.43M | 17.04M | 12.75M |
| Net profit | 20.64M | 19.83M | 108.56M | 14.02M | 38.60M | 25.99M |
| Basic EPS | 0 | 0 | 1 | 0 | 0 | 0 |
| Diluted EPS | 0.30 | 0.28 | 1.26 | 0.16 | 0.43 | 0.29 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 18.67M | 29.35M | 48.18M | 66.47M | 59.55M | 79.45M | 114.58M | 367.05M |
| Cash & ST investments | 17.62M | 28.33M | 46.35M | 65.47M | 58.79M | 76.03M | 51.69M | 148.53M |
| Inventory | 428.52K | 338.47K | 143.56K | 3.01K | 0 | 2.11M | 7.60M | 29.72M |
| Total assets | 18.83M | 29.48M | 49.31M | 68.95M | 62.04M | 82.06M | 118.85M | 826.14M |
| Total current liabilities | 7.77M | 5.83M | 4.16M | 5.35M | 6.31M | 11.40M | 33.84M | 174.27M |
| Short-term debt | -- | 2.01K | 109.13K | 121.37K | 134.80K | 150.62K | 168.00K | 1.45M |
| Long-term debt | 6.13M | -- | -- | -- | -- | -- | -- | 144.63M |
| Total liabilities | 13,891,658.00 | 5,829,650.00 | 5,085,291.00 | 6,147,509.00 | 6,978,523.00 | 11,917,528.00 | 34,189,000.00 | 420,835,000.00 |
| Total equity | 4.93M | 23.65M | 44.22M | 62.80M | 55.06M | 70.14M | 84.66M | 405.31M |
| Retained earnings | -178.99M | -195.42M | -217.45M | -245.66M | -275.36M | -321.70M | -339.63M | -176.58M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 144.86M | 248.06M | 259.54M | 367.05M | 383.11M | 480.55M |
| Cash & ST investments | 77.50M | 190.71M | 55.72M | 148.53M | 178.09M | 256.69M |
| Inventory | 7.49M | 9.63M | 28.92M | 29.72M | 30.73M | 38.58M |
| Total assets | 149.58M | 252.60M | 750.86M | 826.14M | 815.64M | 904.05M |
| Total current liabilities | 34.39M | 31.71M | 133.64M | 174.27M | 128.78M | 187.40M |
| Short-term debt | 172.50K | 177.17K | 1.42M | 1.45M | -- | -- |
| Long-term debt | -- | -- | 144.53M | 144.63M | 144.89M | 145.15M |
| Total liabilities | 34,694,718.00 | 31,968,916.00 | 376,732,072.00 | 420,835,000.00 | 378,588,000.00 | 443,219,000.00 |
| Total equity | 114.89M | 220.63M | 374.13M | 405.31M | 437.05M | 460.83M |
| Retained earnings | -318.99M | -299.16M | -190.60M | -176.58M | -137.97M | -111.99M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -23.70M | -15.05M | -21.97M | -21.16M | -24.36M | -38.41M | -50.62M | 175.05M |
| Depreciation & amortization | 74.22K | 73.29K | 127.96K | 61.89K | 84.62K | 70.76K | 310.00K | 14.55M |
| Free cash flow | -23.75M | -15.09M | -22.08M | -22.58M | -24.58M | -38.74M | -50.73M | 172.79M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 21.97M | 15.23M | 39.69M | 41.46M | 17.77M | 55.83M | 18.88M | 90.16M |
| Ending cash balance | 17.80M | 16.53M | 42.10M | 53.55M | 43.37M | 43.82M | 40.76M | 145.83M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 19.74M | 29.99M | 30.86M | 94.46M | 42.38M | 86.24M |
| Depreciation & amortization | 162.00K | 163.00K | 3.79M | 10.43M | 10.54M | 10.54M |
| Free cash flow | 19.73M | 29.97M | 30.35M | 92.74M | 41.65M | 85.68M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 6.76M | 82.37M | 3.17K | 1.03M | -11.09M | -6.39M |
| Ending cash balance | 66.39M | 159.41M | 49.48M | 145.83M | 179.08M | 257.68M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -442.49 | -304.66 | -64.91 | -52.72 | -50.40 | -74.02 | -23.17 | 66.15 |
| ROA %i | -166.23 | -180.27 | -55.92 | -47.71 | -45.35 | -64.32 | -17.85 | 34.30 |
| ROIC %i | -220.40 | -248.82 | -64.03 | -51.77 | -50.17 | -77.34 | -26.01 | 50.43 |
| 5-year avg ROE %i | -- | -240.61 | -234.23 | -225.76 | -183.04 | -109.34 | -53.04 | -26.83 |
| EBIT margin %i | -6,241.96 | -7,309.87 | -11,354.65 | -15,421.12 | -46,264.69 | -- | -44.37 | 49.02 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | 55.43 |
| Current ratioi | 2.40 | 5.04 | 11.58 | 12.44 | 9.44 | 6.97 | 3.39 | 2.11 |
| Quick ratioi | 2.27 | 4.86 | 11.14 | 12.26 | 9.32 | 6.67 | 3.05 | 1.83 |
| Debt / assetsi | 32.54 | 0.02 | 2.09 | 1.34 | 1.29 | 0.81 | 0.44 | 18.03 |
| LT debt / equityi | 124.15 | 0.01 | 2.09 | 1.28 | 1.21 | 0.74 | 0.41 | 36.38 |
| Interest coveragei | -14,323.42 | -26.29 | -817.55 | -1,846.86 | -1,141.27 | -1,350.16 | -529.83 | 54.92 |
| Revenue CAGR (3Y) %i | 26.94 | 8.12 | -10.11 | -23.70 | -38.65 | -- | 510.62 | 1,582.83 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 19.87 | 38.35 | 75.08 | 66.15 | 65.19 | 54.64 |
| ROA %i | 15.79 | 32.97 | 39.23 | 34.30 | 37.28 | 32.19 |
| ROIC %i | 17.16 | 36.41 | 55.14 | 50.43 | 51.61 | 45.03 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 20.86 | 42.57 | 50.40 | 49.02 | 49.08 | 48.05 |
| FCF / sales %i | -- | 25.03 | 34.73 | 55.43 | 48.67 | 54.77 |
| Current ratioi | 4.21 | 7.82 | 1.94 | 2.11 | 2.98 | 2.56 |
| Quick ratioi | 3.84 | 7.37 | 1.61 | 1.83 | 2.59 | 2.23 |
| Debt / assetsi | 0.32 | 0.17 | 19.83 | 18.03 | 17.76 | 16.06 |
| LT debt / equityi | 0.26 | 0.12 | 39.42 | 36.38 | 33.15 | 31.50 |
| Interest coveragei | 470.69 | 1,409.47 | 110.79 | 54.92 | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- DefenCath is the largest reported line at 66.58% of revenue, across 3 reported segments.
- Melinta Portfolio follows at 28.42%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
DefenCath66.58%
Melinta Portfolio28.42%
Contract revenue5.00%
Quote time 2026-10-08 09:20:33 · For reference only, not investment advice and not tailored to your situation.